Autolus Therapeutics AUTL 深 沪
等待开盘 05-12 09:30:00 美东时间
1.5994
+0.014
+0.91%
华盛通- 最 高1.75
- 今 开1.59
- 成交量 106.08万股
- 最 低 1.55
- 昨 收 1.585
- 总市值 14.54万
- 52周最高 2.70
- 市盈率 静 --
- 换手率 1166.79%
- 52周最低 1.175
- 委 比 -28.03%
- 总股本 9.09万
- 历史最高 53.24
- 量 比 0.91
- 振 幅 12.62%
- 历史最低 1.10
- 每 手 1
- 风险率 0.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For March 27, 2026
Companies Reporting Before The Bell • Instil Bio (NASDAQ:TIL) is expected to re...
03-27 19:11
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
Autolus Therapeutics reports updated long-term data from the FELIX study of obe-cel in adult r/r B-ALL patients, showing a median response duration of 42.6 months, with over half of patients in remission at 24 months and 38% not requiring subsequent therapy by month 33. The results suggest obe-cel may offer durable, definitive treatment for some patients.
2025-06-12 06:00
Autolus Therapeutics to Participate in Upcoming Investor Conferences
Autolus Therapeutics (Nasdaq: AUTL) announced its participation in three upcoming investor conferences: June 3 in Chicago, June 5 in New York, and June 11 in Miami.
2025-05-29 20:05
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Autolus Therapeutics' obe-cel CAR T-cell therapy received a positive CHMP opinion, based on the FELIX trial showing high response rates and low toxicity for adult r/r B-ALL patients. The EC is expected to decide on conditional marketing authorization within two months, following FDA and MHRA approvals.
2025-05-23 12:30
European Equities Traded in the US as American Depositary Receipts Edge Lower Friday; Set to End Week Up 0.5%
11:10 AM EDT, 08/30/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts edged lower late Friday morning, nudging down 0.03% to 1,476.31 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and ...
2024-08-30 23:10
Autolus Therapeutics to Present Tumor Burden-Guided Dosing Data at SOHO 2024
Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces a poster presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting being held September 4-7, 2024 in Houston, Texas. These data demonst...
2024-08-27 19:02
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
11:19 AM EDT, 08/15/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts were higher late Thursday morning, rising 1.22% to 1,444.66 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by telecommunications company Nokia (NOK) and in...
2024-08-15 23:19
